Inhibiting Myostatin Expression by the Antisense Oligonucleotides Improves Muscle Wasting in a Chronic Kidney Disease Mouse Model
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26073098 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Arju Akhter und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Faculty of Medicine, Shimane University, 89-1 Enya-Cho, Izumo 693-8501, Japan. Hauptthemen laut MEDLINE: Myostatin, Renal Insufficiency, Chronic, Oligonucleotides, Antisense, Muscular Atrophy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Project for Practical Application of Rare and Intractable Diseases, Japan Agency for Medical Research and Development (AMED).
Abstract (Originalsprache)
Sarcopenia, a serious consequence of chronic kidney disease (CKD), is driven by elevated myostatin (MSTN), a key inhibitor of muscle growth. This study explored the potential of an MSTN-specific antisense oligonucleotide (ASO) in reversing CKD-induced muscle wasting in a mouse model. Thirty-two male C57BL/6J mice were randomly assigned to a non-CKD group (n = 8, regular diet) and a CKD group (n = 24, adenine diet). CKD was induced using a 0.2% adenine-supplemented diet for 4 weeks. Following this, the mice were sub-grouped into CKD (saline, n = 8), CKD + Low-Dose ASO (25 mg/kg ASO, n = 8), and CKD + High-Dose ASO (50 mg/kg ASO, n = 8). ASO was administered via subcutaneous injections for 8 weeks. Muscle mass, treadmill performance, grip strength, and muscle fiber morphology were assessed alongside qPCR and Western blot analysis for MSTN, atrogin-1, and MuRF-1 expression. ASO therapy significantly enhanced muscle mass and function and enlarged muscle fibers while effectively downregulating muscle degradation markers. These improvements occurred without compromising renal function, as confirmed by BUN, creatinine, kidney weight, and histological analysis. This study is the first to demonstrate the efficacy of ASO therapy in mitigating CKD-induced sarcopenia, offering a promising targeted gene therapy with significant clinical implications for improving nutritional status and physical performance in CKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Faculty of Medicine, Shimane University, 89-1 Enya-Cho, Izumo 693-8501, Japan.
- Department of Nephrology, Faculty of Medicine, Shimane University, 89-1 Enya-Cho, Izumo 693-8501, Japan.
- The Center for Integrated Kidney Research and Advance (IKRA), Faculty of Medicine, Shimane University, 89-1 Enya-Cho, Izumo 693-8501, Japan.
- Department of Neurology, Faculty of Medicine, Shimane University, 89-1 Enya-Cho, Izumo 693-8501, Japan.
- Graduate School of Science, Technology and Innovation, Kobe University, Kobe 657-8501, Japan.
ORCID-Profile: Arju Akhter, Abdullah Md Sheikh, Jun Yoshino, Atsushi Nagai, Masafumi Matsuo, Shozo Yano
Förderung
- Research Project for Practical Application of Rare and Intractable Diseases, Japan Agency for Medical Research and Development (AMED)
Zitieren
APA
Akhter, A., Md Sheikh, A., Yoshino, J., Kanda, T., Nagai, A., Matsuo, M., & Yano, S. (2025). Inhibiting Myostatin Expression by the Antisense Oligonucleotides Improves Muscle Wasting in a Chronic Kidney Disease Mouse Model. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26073098
Vancouver
Akhter A, Md Sheikh A, Yoshino J, Kanda T, Nagai A, Matsuo M, et al. Inhibiting Myostatin Expression by the Antisense Oligonucleotides Improves Muscle Wasting in a Chronic Kidney Disease Mouse Model. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26073098
BibTeX
@article{Akhter2025,
author = {Akhter, Arju and Md Sheikh, Abdullah and Yoshino, Jun and Kanda, Takeshi and Nagai, Atsushi and Matsuo, Masafumi and Yano, Shozo},
title = {Inhibiting Myostatin Expression by the Antisense Oligonucleotides Improves Muscle Wasting in a Chronic Kidney Disease Mouse Model},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26073098}
}
EUVIMED